A016450 KR7016450009

Bericht

Schlusskurs Korea Stock Exchange - 12.08.2022
5860.00	KRW		+0.69%

16.05.	Hansae Yes24 Holdings Co., Ltd. meldet Ergebnis für das erste Quartal zum 31. März 2022	CI
21.03.	Hansae Yes24 Holdings Co., Ltd. meldet Ergebnis für das Geschäftsjahr zum 31. Dezember 2021	CI

News

Andere Sprachen

Offizielle Publikationen

Branchen-News

Nachrichten in anderen Sprachen über HANSAE YES24 HOLDINGS CO., LTD

10.08.	European Society for Organ Transplantation's (ESOT) guidelines for desensitization trea..
19.07.	Hansa Biopharma half year report 2022
18.07.	Hansa Biopharma announces $70 million non-dilutive product finance transaction with Nov..
11.07.	Hansa Biopharma announces first patient treated in the post-authorization efficacy stud..
30.06.	Increase of the number of votes in Hansa Biopharma
30.06.	Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
30.06.	Hansa Biopharma to host conference call to provide half year results for January-June 2..
16.06.	NICE recommends use of Hansa Biopharma's Idefirix® (imlifidase) as desensitization trea..
30.05.	HANSA BIOPHARMA : Notice to Annual General Meeting
30.05.	The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the ..
23.05.	Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated r..
16.05.	Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the First Quarter Ended Mar..
13.05.	Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix..
21.04.	Hansa Biopharma interim report January - March 2022
20.04.	Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idef..
19.04.	Hansa Biopharma announces U.S. FDA acceptance of Investigational New Drug (IND) applica..
07.04.	Hansa Biopharma publishes Annual Report 2021
28.03.	Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefi..
21.03.	Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Full Year Ended Decembe..
15.03.	Hansa Biopharma and German payer head association agree on reimbursement price for Idef..
08.03.	Key data demonstrating the potential of Hansa Biopharma's imlifidase to significantly a..
25.02.	Hansa Biopharma announces positive early access decision by French Haute Autorité de Sa..
03.02.	Hansa Biopharma year-end report 2021
20.01.	Hansa Biopharma to host conference call to provide Year-End report for 2021 and Busines..
09.01.	Hansa Biopharma provides business update including certain key financials
03.01.	Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase..
2021	Increase of the number of shares and votes in Hansa Biopharma AB
2021	Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of i..
2021	HANSA BIOPHARMA : Issue and repurchase of class C shares for incentive programs
2021	Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership..
2021	Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Third Quarter and Nine ..
2021	Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Baseme..
2021	Hansa Biopharma Nomination Committee formed
2021	Hansa Biopharma announces it has confidentially submitted a draft registration statemen..
2021	HANSA BIOPHARMA : interim report Jan-Sept 2021
2021	HANSA BIOPHARMA : to host conference call to provide interim results for January-September..
2021	HANSAE YES24 HOLDINGS CO., LTD(KOSE : A016450) added to S&P Global BMI Index
2021	HANSA BIOPHARMA : presented new data on imlifidase at the European Society for Organ Trans..
2021	HANSA BIOPHARMA : announces participation in Fall investor conferences and provides update..
2021	HANSA BIOPHARMA : achieves Great Place to Work certification for second consecutive year
2021	HANSA BIOPHARMA : announces reimbursement in the Netherlands of Idefirix (imlifidase) as d..
2021	HANSA BIOPHARMA : interim report Jan-June 2021
2021	HANSA BIOPHARMA : announces long term follow-up data demonstrating 3-year graft survival o..
2021	HANSA BIOPHARMA : to host conference call to provide interim results for first half 2021 a..
2021	HANSA BIOPHARMA : announces decision by Swedish New Therapies Council to recommend use of ..
2021	HANSA BIOPHARMA : announces study design for a US randomized, controlled trial of imlifida..
2021	HANSA BIOPHARMA : Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
2021	HANSA BIOPHARMA : interim report Jan-Mar 2021
2021	HANSA BIOPHARMA : to host conference call to provide interim results from Q1 2021 and Busi..
2021	HANSA BIOPHARMA : Notice to Annual General Meeting
2021	HANSA BIOPHARMA : publishes Annual Report 2020
2021	HANSA BIOPHARMA : enters preclinical research collaboration with argenx
2021	HANSA BIOPHARMA : appoints Dr. Magnus Korsgren as Head of Research & Development
2021	HANSA BIOPHARMA : year-end report Jan-Dec 2020
2021	HANSA BIOPHARMA : to host conference call to provide Year-End report 2020 and Business Upd..
2020	HANSA BIOPHARMA : Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conferen..
2020	KakaoBank of Korea Corp. cancelled the acquisition of 5.1% stake in Hansae Yes24 Holdin..
2020	HANSA BIOPHARMA : Nomination Committee formed
2020	Hansa Biopharma interim report Jan-Sep 2020
2020	HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-initiated ..
2020	HANSAE YES24 HOLDINGS CO., LTD(KOSE : A016450) dropped from S&P Global BMI Index
2020	HANSA BIOPHARMA : Biopharma to host Capital Markets Day on Thursday October 29, 2020 in C..
2020	HANSA BIOPHARMA : certified as a Great Place to Work
2020	HANSA BIOPHARMA : provides updated guidance on its clinical programs
2020	HANSA BIOPHARMA : announces participation in Fall conferences and an updated financial cal..
2020	HANSA BIOPHARMA PUBL : announces increase in number of shares and votes
2020	HANSA BIOPHARMA PUBL : expands the leadership team with the appointment of Katja Margell a..
2020	Hansa Biopharma interim report Jan-Jun 2020
2020	HANSA BIOPHARMA PUBL : announces successful completion of SEK 1.1bn (USD 121m) placing of ..
2020	HANSA BIOPHARMA PUBL : announces intention to carry out a placing of new ordinary shares
2020	Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and ..
2020	HANSA BIOPHARMA PUBL : to host conference call to provide interim results for the first ha..
2020	HANSA BIOPHARMA PUBL : receives positive CHMP opinion for Idefirix (imlifidase) for kidney..
2020	HANSA BIOPHARMA PUBL : Bulletin from the Annual General Meeting in Hansa Biopharma AB (pub..
2020	HANSA BIOPHARMA PUBL : appoints Achim Kaufhold as CMO to support the expansion outside tra..

1 2 Weiter

Anstehende Termine für HANSAE YES24 HOLDINGS CO., LTD

16.08.22

Erstes Halbjahr 2022 Ergebnisveröffentlichung (geplant)

Finanzkalender des Unternehmens

Anstehende Branchentermine

01.09.22	LULULEMON ATHLETICA INC. : Erstes Halbjahr 2022 Ergebnisveröffentlichung (geplant)
21.10.22	V.F. CORPORATION : Erstes Halbjahr 2023 Ergebnisveröffentlichung (geplant)
08.12.22	LULULEMON ATHLETICA INC. : Q3 2022 Ergebnisveröffentlichung (geplant)
26.01.23	V.F. CORPORATION : Q3 2023 Ergebnisveröffentlichung (geplant)

Mehr Termine

Branche

Zyklische Konsumgüter
	Zyklische Konsumgüter
		Textil - Kleidung
			Kleidung und Accessoires
				Bekleidung und Accessoires - Andere